{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:29:26Z","timestamp":1793773766055,"version":"4.6.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.clml.2022.10.008","type":"journal-article","created":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T12:20:18Z","timestamp":1666441218000},"page":"e41-e50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4230-8356","authenticated-orcid":false,"given":"David M.","family":"Foureau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry A.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward H.","family":"Lipford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kateryna","family":"Fesenkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Tjaden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4595-6984","authenticated-orcid":false,"given":"Kendra","family":"Drummond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Bhutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4547-7534","authenticated-orcid":false,"given":"Shebli","family":"Atrash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Ndiaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Voorhees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.10.008_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2020.00001","article-title":"Clinical applications and future directions of minimal residual disease testing in multiple Myeloma","volume":"10","author":"Oliva","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2022.10.008_bib0002","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.10.008_bib0003","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-020-00911-4","article-title":"Measurable residual disease in multiple myeloma: ready for clinical practice?","volume":"13","author":"Burgos","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2022.10.008_bib0004","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.clml.2019.09.622","article-title":"Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a meta-analysis","volume":"20","author":"Avet-Loiseau","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.10.008_bib0005","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.10.008_bib0006","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.10.008_bib0007","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2020-138485","article-title":"Response-adaptive phase II study of daratumumab combined with carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma","volume":"136","author":"Bhutani","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.10.008_bib0008","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma workshop consensus panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2022.10.008_bib0009","article-title":"Harmonization of flow cytometric minimal residual disease assessment in multiple myeloma in centers of polish myeloma consortium","volume":"11","author":"Krzywdzinska","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.clml.2022.10.008_bib0010","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41408-020-00377-0","article-title":"Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma","volume":"10","author":"Medina","year":"2020","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.clml.2022.10.008_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082322","article-title":"Comparison of NGS and MFC methods: key metrics in multiple myeloma MRD assessment","volume":"12","author":"Kriegsmann","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2022.10.008_bib0012","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1182\/blood-2019-124645","article-title":"Minimal residual disease evaluation by multiparameter flow cytometry and next generation sequencing in the forte trial for newly diagnosed multiple myeloma patients","volume":"134","author":"Oliva","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2022.10.008_bib0013","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/cyto.b.20512","article-title":"Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders","volume":"78","author":"Paiva","year":"2010","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.clml.2022.10.008_bib0014","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cyto.b.21265","article-title":"Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma","volume":"90","author":"Flores-Montero","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.clml.2022.10.008_bib0015","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.10.008_bib0016","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/cyto.b.22053","article-title":"Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: an international harmonized approach for data analysis","volume":"102","author":"Soh","year":"2022","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"10.1016\/j.clml.2022.10.008_bib0017","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/ijlh.13562","article-title":"Evaluation of measurable residual disease in multiple myeloma by multiparametric flow cytometry: current paradigm, guidelines, and future applications","volume":"43","author":"Soh","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.clml.2022.10.008_bib0018","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/cyto.b.21104","article-title":"Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part I - rationale and aims","volume":"84","author":"Davis","year":"2013","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.clml.2022.10.008_bib0019","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/bloodadvances.2020002037","article-title":"Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma","volume":"4","author":"Martinez-Lopez","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.10.008_bib0020","doi-asserted-by":"crossref","first-page":"7476","DOI":"10.1038\/s41598-018-25895-7","article-title":"Exploring DNA quality of single cells for genome analysis with simultaneous whole-genome amplification","volume":"8","author":"Baumer","year":"2018","journal-title":"Sci Rep"},{"issue":"19","key":"10.1016\/j.clml.2022.10.008_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194924","article-title":"Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma","volume":"13","author":"Puig","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2022.10.008_bib0022","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.semcancer.2010.04.003","article-title":"Adhesion molecules\u2013The lifelines of multiple myeloma cells","volume":"20","author":"Katz","year":"2010","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.clml.2022.10.008_bib0023","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41232-020-00113-y","article-title":"Integrins in multiple myeloma","volume":"40","author":"Hosen","year":"2020","journal-title":"Inflamm Regen"},{"key":"10.1016\/j.clml.2022.10.008_bib0024","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00256-020-03423-x","article-title":"CT-guided bone marrow aspirations and biopsies: retrospective study and comparison with blind procedures","volume":"49","author":"Chang","year":"2020","journal-title":"Skeletal Radiol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:40:59Z","timestamp":1761871259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022017165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2152265022017165"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.10.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}